A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCTIVITIS +/- ASTHMA SENSITIZED TO DERMATOPHAGOIDES PTERONYSSINUS.

A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCTIVITIS +/- ASTHMA SENSITIZED TO DERMATOPHAGOIDES PTERONYSSINUS. - BIAL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-004583-30-ES

Enrollment

150

Registered

2011-11-07

Start date

2012-01-16

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinoconjunctivitis with or without associated asthma.

Interventions

Product Name: Allegovac depot. Product Code: V01AA Pharmaceutical Form: Suspension for injection CAS Number: 8000045207 Other descriptive name: Allergens, house dust and mite Concentration unit: SU/ml

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 150 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: Compare the efficacy of subcutaneous immunotherapy in depot presentation in five different doses in sensitive patients to Dermatophagoides pteronyssinus with asthma +/- allergic rhinoconjunctivitis, between 18 and 60 years old.;Secondary Objective: Not applicable;Primary end point(s):	—

Countries

Spain

Contacts

Public ContactCAIBER

CAIBER

ugoicoechea@caiber.net003491822249400

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026